Neomycinum (Neomycin Sulfate)

Neomycin Sulfate interferes with bacterial protein synthesis by binding to the 30S ribosomal subunit. This binding blocks the formation of the initiation complex, halting production of essential proteins and leading to bacterial cell death or growth inhibition on the ocular surface.

The dosing regimen for Neomycinum is determined by the prescribing clinician based on the severity of the infection, patient age, and response to therapy. The prescriber will specify the number of drops, frequency, and duration appropriate for each case.

Safety data for Neomycinum in pregnancy and lactation are limited. It should be used only if the prescriber judges that the potential benefit justifies any possible risk to the fetus or infant. Consultation with a healthcare professional is essential.

To request Neomycinum, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Neomycinum belongs to the aminoglycoside class, offering broad‑spectrum activity against many Gram‑negative and some Gram‑positive ocular pathogens. Compared with fluoroquinolone eye drops, it may have a different resistance profile and is often used when a clinician prefers an aminoglycoside or when specific bacterial sensitivities are known.

Neomycinum should be stored at room temperature, below 25 °C, in its original container. Protect the product from direct light and moisture to maintain stability. Do not freeze the solution.

Neomycinum is applied as eye drops. The prescriber will instruct the patient on the number of drops per eye, the frequency (e.g., every 2–4 hours), and the total duration of therapy. Hands should be washed before use, and the dropper tip should avoid contact with the eye or surrounding tissues.

Serious risks, though uncommon, include allergic contact dermatitis of the eyelid or peri‑ocular skin, corneal ulceration, severe eye pain, vision loss, and rare systemic toxicity such as nephrotoxicity or ototoxicity if significant systemic absorption occurs.

Neomycinum should not be used by individuals with a known hypersensitivity to neomycin, other aminoglycosides, or any component of the formulation. It is also contraindicated in patients with active viral or fungal eye infections unless specifically directed by a specialist.